Edition:
United States

Merrimack Pharmaceuticals Inc (MACK.OQ)

MACK.OQ on NASDAQ Stock Exchange Global Market

4.98USD
17 Jan 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.98
Open
$4.93
Day's High
$5.04
Day's Low
$4.93
Volume
9,336
Avg. Vol
15,765
52-wk High
$11.70
52-wk Low
$3.35

Latest Key Developments (Source: Significant Developments)

Merrimack Q3 Loss Per Share $0.92 From Continuing Operations
Wednesday, 7 Nov 2018 06:45am EST 

Nov 7 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES STRATEGIC UPDATE FOLLOWING PORTFOLIO REVIEW.Q3 LOSS PER SHARE $0.92 FROM CONTINUING OPERATIONS.Q3 EARNINGS PER SHARE VIEW $-0.27 -- THOMSON REUTERS I/B/E/S.MERRIMACK PHARMACEUTICALS-TO INITIATE CORPORATE RESTRUCTURING, INCLUDING ABOUT 60% REDUCTION IN FORCE AND SIGNIFICANT REDUCTION IN OPERATING EXPENSES.TO INITIATE CORPORATE RESTRUCTURING.TO INITIATE ABOUT 60% REDUCTION IN FORCE AND SIGNIFICANT REDUCTION IN OPERATING EXPENSES.HAS ENGAGED EXTERNAL ADVISORS TO EVALUATE STRATEGIC ALTERNATIVES.DISCONTINUING DEVELOPMENT OF ALL ONGOING MM-121 PROGRAMS.POTENTIAL TO EXTEND RUNWAY INTO AT LEAST 2H 2022 TO PRESERVE ABILITY TO CAPTURE IPSEN MILESTONES.WILL FOCUS PROGRAM SPENDING ON PHASE 1 STUDY OF MM-310, WITH SAFETY UPDATE ANTICIPATED IN Q1 2019."PRUDENT" ADVANCEMENT OF PRECLINICAL CANDIDATES, MM-401 AND MM-201.QTRLY LOSS PER SHARE $0.92 FROM CONTINUING OPERATIONS.TERMINATION OF PHASE 2 SHERBOC STUDY IN METASTATIC BREAST CANCER.ELIMINATION OF ALL OPEN POSITIONS, TO BE INITIATED IMMEDIATELY AND COMPLETED BY FEBRUARY 2019.HAS POTENTIAL TO FUND ITS OPERATIONS INTO AT LEAST SECOND HALF OF 2022.QTRLY EARNINGS PER SHARE $0.30.  Full Article

JFL Capital Management Reports 7.1 Pct Stake In Merrimack Pharmaceuticals
Friday, 2 Nov 2018 05:58pm EDT 

Nov 2 (Reuters) - Merrimack Pharmaceuticals Inc ::JFL CAPITAL MANAGEMENT LLC REPORTS 7.1 PERCENT STAKE IN MERRIMACK PHARMACEUTICALS INC AS OF OCTOBER 23, 2018 - SEC FILING.JFL CAPITAL MANAGEMENT LLC BELIEVE THAT SHARES OF MERRIMACK PHARMACEUTICALS WHEN PURCHASED, WERE UNDERVALUED.  Full Article

Merrimack Reports Q2 Loss Per Share $1.33
Tuesday, 7 Aug 2018 06:30am EDT 

Aug 7 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $1.33.Q2 EARNINGS PER SHARE VIEW $-1.28 -- THOMSON REUTERS I/B/E/S.MERRIMACK - BELIEVES CURRENT RESOURCES SUFFICIENT TO FUND PLANNED OPERATIONS INTO AT LEAST Q1 2020.  Full Article

Merrimack Pharmaceuticals Reports Q1 Operating Loss Per Share Of $1.33
Tuesday, 8 May 2018 06:25am EDT 

May 8 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 OPERATING LOSS PER SHARE $1.33.THREE CLINICAL READOUTS EXPECTED IN 2018, INCLUDING DATA FROM TWO RANDOMIZED PHASE 2 STUDIES.MERRIMACK - BELIEVE CASH,CASH EQUIVALENTS OF $76.3 MILLION AS OF MARCH 31&SOME MILESTONE PAYMENTS ANTICIPATED FROM SHIRE TO BE ENOUGH TO FUND INTO H2 2019.  Full Article

Merrimack Provides Business Update And Reports 2017 Financial Results
Monday, 12 Mar 2018 06:27am EDT 

March 12 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK PROVIDES BUSINESS UPDATE AND REPORTS 2017 FINANCIAL RESULTS.‍EXPECTS THREE CLINICAL READOUTS IN 2018, INCLUDING DATA FROM TWO RANDOMIZED PHASE 2 STUDIES​.‍ANNOUNCED FORMATION OF A NEW SCIENTIFIC ADVISORY BOARD WITH EXPERTISE IN PRECISION ONCOLOGY​.MERRIMACK PHARMACEUTICALS -‍ CLOSURE OF 2017 WITH $93.4 MILLION IN CASH, CASH EQUIVALENTS, EXTINGUISHMENT OF $60.8 MILLION OF CONVERTIBLE DEBT IN Q4​.MERRIMACK PHARMACEUTICALS - CONTINUES TO BELIEVE THAT CASH & CASH EQUIVALENTS AS OF DEC 31, 2017 WILL BE SUFFICIENT TO FUND PLANNED OPERATIONS INTO H2 2019.Q4 LOSS PER SHARE $0.89.  Full Article

Merrimack Strengthens SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer
Monday, 12 Mar 2018 06:25am EDT 

March 12 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK STRENGTHENS SHERLOC STUDY OF MM-121 IN NON-SMALL CELL LUNG CANCER.MERRIMACK PHARMACEUTICALS INC - ‍RANDOMIZED PHASE 2 STUDY ACCRUAL RAISED TO 100 PATIENTS; DATA STILL EXPECTED LATER THIS YEAR​.MERRIMACK PHARMACEUTICALS INC - ‍MERRIMACK CONTINUES TO ANTICIPATE TOP-LINE DATA FROM SHERLOC STUDY IN SECOND HALF OF 2018​.  Full Article

Merrimack Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln
Friday, 15 Dec 2017 04:40pm EST 

Dec 15 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Merrimack reports Q3 loss per share from continuing operations $0.40
Wednesday, 8 Nov 2017 06:40am EST 

Nov 8 (Reuters) - Merrimack Pharmaceuticals Inc :Merrimack reports third quarter 2017 financial results.Merrimack Pharmaceuticals Inc - Qtrly loss per share from continuing operations $0.40.Merrimack Pharmaceuticals-Believes unrestricted cash & cash equivalents & payments from shire will be sufficient to fund operations into H2 2019.  Full Article

Merrimack receives orphan drug designation for MM-121 for the treatment of type of lung cancer
Monday, 30 Oct 2017 06:55am EDT 

Oct 30 (Reuters) - Merrimack Pharmaceuticals Inc :Merrimack receives orphan drug designation for MM-121 for the treatment of heregulin positive non-small cell lung cancer.Merrimack Pharmaceuticals - ‍orphan drug designation by FDA includes eligibility for 7-year period of marketing exclusivity for MM-121 upon approval​.Merrimack Pharmaceuticals - ‍MM-121 is currently being evaluated in SHERLOC study; top-line data for SHERLOC study is expected in H2 2018​.  Full Article

Merrimack commences tender offer for outstanding 4.50 pct convertible senior notes
Friday, 13 Oct 2017 07:30am EDT 

Oct 13 (Reuters) - Merrimack Pharmaceuticals Inc ::Merrimack commences tender offer for any and all of its outstanding 4.50 pct convertible senior notes due 2020.Merrimack Pharmaceuticals-commenced tender offer to buy $25.03 million aggregate principal amount of outstanding 4.50 pct convertible senior notes due 2020​.  Full Article

Ex-Merrimack Pharmaceuticals employee gets prison for insider trading

A former Merrimack Pharmaceuticals Inc employee was sentenced on Tuesday to six months in prison after being convicted of participating in an insider trading scheme with a friend at a rival biopharmaceutical company.